The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Use of metformin and the risk of ovarian cancer: A case–control analysis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 2×
“A mounting body of recent evidence suggests that use of the biguanide drug metformin, a widely used oral antidiabetic agent, may exert protective effects against cancer development [3–5], may be associated with decreased cancer-related mortality as compared to use of insulin or sulfonylureas [6], and may improve progn…”
BackgroundResultThe influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“A mounting body of recent evidence suggests that use of the biguanide drug metformin, a widely used oral antidiabetic agent, may exert protective effects against cancer development [3–5], may be associated with decreased cancer-related mortality as compared to use of insulin or sulfonylureas [6], and may improve progn…”
BackgroundMetformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 1×
“A mounting body of recent evidence suggests that use of the biguanide drug metformin, a widely used oral antidiabetic agent, may exert protective effects against cancer development [3–5], may be associated with decreased cancer-related mortality as compared to use of insulin or sulfonylureas [6], and may improve progn…”
BackgroundMetformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Cited by
Epidemiology of ovarian cancer: a review
Brett M., R., Brett M., R., Jennifer B., P., Thomas A., S., Jennifer B., P., & Thomas A., S. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0084 · Cited by 1,524
Epidemiology of epithelial ovarian cancer
Webb, P. M., & Jordan, S. J. (2017) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.08.006 · Cited by 995
Barry, J. A., Azizia, M. M., & Hardiman, P. J. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu012 · Cited by 597
Metformin and the Risk of Cancer
Suissa, S., & Azoulay, L. (2012) · Diabetes Care · doi:10.2337/dc12-0788 · Cited by 531
Endometriosis: a high-risk population for major chronic diseases?
Kvaskoff, M., Mu, F., Terry, K. L., Harris, H. R., Poole, E. M., Farland, L., & Missmer, S. A. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv013 · Cited by 439
Metadata
- Authors
- Bodmer, M., Becker, C., Meier, C., Jick, S. S., & Meier, C. R.
- Venue
- Gynecologic Oncology
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 123
- Issue
- 2
- Pages
- 200-204
- ISSN
- 0090-8258 (ISSN-L)
- OpenAlex
- W2149258144
- Cited by
- 159
- References
- 6
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.